Get the Stockscreener App
2.99
8.33%
0.23
After Hours:
3.00
0.010
+0.33%
Sight Sciences Inc stock is traded at $2.99, with a volume of 164.92K.
It is up +8.33% in the last 24 hours and up +3.46% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$2.76
Open:
$2.81
24h Volume:
164.92K
Relative Volume:
0.67
Market Cap:
$129.36M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-2.6228
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
+18.65%
1M Performance:
+3.46%
6M Performance:
-47.08%
1Y Performance:
-44.32%
1-Day Range:
$2.78
$3.00
1-Week Range:
$2.3998
$3.00
52-Week Range:
$2.03
$8.45
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
2.99 | 129.36M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight Sciences Appoints Gary Burbach to Board of Directors - VisionMonday.com
Sight Sciences appoints new board member By Investing.com - Investing.com India
Sight Sciences appoints new board member - Investing.com
Sight Sciences Appoints Gary Burbach to its Board of Directors - The Manila Times
Sight Sciences Strengthens Board with Medtech Veteran as Glaucoma, Dry Eye Markets Transform - Stock Titan
Sight Sciences Launches OMNI® Edge Surgical System to Enhance Glaucoma Treatment - Nasdaq
Sight Sciences to Debut OMNI® Edge Surgical System at the - GlobeNewswire
Sight Sciences Unveils OMNI Edge: Next-Gen Glaucoma Surgery System with 2X Capacity | SGHT Stock News - Stock Titan
Sight Sciences, Inc. (NASDAQ:SGHT) Shares Acquired by American Century Companies Inc. - Defense World
Sight Sciences (NASDAQ:SGHT) Earns Hold Rating from Needham & Company LLC - Defense World
Sight sciences CTO David Badawi sells $15,081 in stock - MSN
April 2025's Top Penny Stocks To Watch - simplywall.st
Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Sight Sciences at 24th Annual Needham Conference: Strategic Growth Insights - Investing.com Canada
Sight sciences chief commercial officer sells $11,641 in stock By Investing.com - Investing.com India
Sight Sciences stock hits 52-week low at $2.13 amid market challenges - Investing.com
Sight sciences chief commercial officer sells $11,641 in stock - Investing.com
Sight sciences CEO Paul Badawi sells shares worth $55,672 By Investing.com - Investing.com Australia
Sight sciences CTO David Badawi sells $13,771 in common stock By Investing.com - Investing.com India
Sight Sciences CFO Alison Bauerlein sells shares worth $44,787 By Investing.com - Investing.com Australia
Sight Sciences CFO Alison Bauerlein sells shares worth $44,787 - Investing.com
Sight sciences CTO David Badawi sells $13,771 in common stock - Investing.com
Sight Sciences chief legal officer sells $21,693 in stock - Investing.com
Sight Sciences chief legal officer sells $21,693 in stock By Investing.com - Investing.com UK
Sight Sciences Executives Sell Shares to Cover Tax Liabilities - TradingView
Sight Sciences stock hits 52-week low at $2.13 amid market challenges By Investing.com - Investing.com South Africa
Sight Sciences, Inc. (NASDAQ:SGHT) Short Interest Update - Defense World
Charles Schwab Investment Management Inc. Raises Stock Position in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Sight sciences chief legal officer sells shares worth $19,250 - MSN
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th - GlobeNewswire
Key Investor Updates Coming: Sight Sciences Takes Center Stage at Major Healthcare Conference - Stock Titan
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Sight sciences EVP Manohar Raheja buys $53,250 in stock By Investing.com - Investing.com Australia
Sight sciences EVP Manohar Raheja buys $53,250 in stock - Investing.com India
Piper Sandler Cuts Sight Sciences (NASDAQ:SGHT) Price Target to $3.50 - Defense World
Sight Sciences’ (SGHT) Hold Rating Reiterated at Needham & Company LLC - Defense World
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics - MSN
Lake Street Capital Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Stifel Nicolaus Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts By Investing.com - Investing.com Australia
Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Sight Sciences Inc. (SGHT) reports earnings - Quartz
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results, Initiates Full Year 2025 Financial Guidance - Vision Monday
Sight Sciences Faces Headwinds in Glaucoma and Dry Eye Markets, Hold Rating Maintained - TipRanks
Sight Sciences’ Earnings Call: Cautious Optimism Amid Challenges - TipRanks
Sight Sciences price target lowered to $3.50 from $5.50 at Piper Sandler - TipRanks
Stifel cuts Sight Sciences price target to $4, maintains Buy rating By Investing.com - Investing.com South Africa
Stifel cuts Sight Sciences price target to $4, maintains Buy rating - Investing.com
Sight Sciences Stock Hits 52-Week Low at $2.27 Amid Market Challenges - Investing.com India
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):